Egetis Therapeutics AB (publ) Receivables

Egetis Therapeutics AB (publ) (EGTX.ST) currently reports a receivables of $31M as of September 2026. That compares with $43M in the prior-year period — down 27.9% year over year. Use the charts on this page to explore Egetis Therapeutics AB (publ)'s receivables history and peer comparisons.

Egetis Therapeutics AB (publ)'s receivables decreased from $43M to $31M — a 27.9% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Egetis Therapeutics AB (publ) reported $31M in receivables as of September 2026. That compares with $43M in the prior-year period — down 27.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Egetis Therapeutics AB (publ), and consider following EGTX.ST for alerts when major investors trade the stock.

Egetis Therapeutics AB (publ) is classified in the Healthcare sector. On receivables, it currently shows $31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EGTX.ST with unrelated industries.